A Phase II Evaluation Of The Safety And Efficacy Of Mirvetuximab Soravtansine (Imgn853) In Women With Folate Receptor-? Positive Persistent Or Recurrent Endometrial Cance
Posted Date: Apr 25, 2024
- Investigator: Amanda Jackson
- Specialties: Cancer, Gynecologic Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRa).
Criteria:
Null
Keywords:
Endometrial
For More Information:
Jessica Mullins
NULL
cancer@uchealth.com